Leuven (BELGIUM) – May 17, 2017, 09:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, announces today that it will be presenting at or attending a series of international scientific and industry conferences in May and June.
TiGenix will be presenting at events including:
• The Advanced Regenerative Medicine Congress, London, UK, May 17 – 19. Ken Genenz, Senior Director for Market Access, will be taking part in the panel discussion on Assessment of Health Technologies and Market Access Globally, Challenges and Pricing.
• CASSS CMC Strategy Forum Europe, Killarny, Ireland, May 22. Maria del Pilar Redondo, Senior Director Technical Operations, will be presenting “A Living Medicine: How to Cope with CMC Requirements in the Development of Cell Therapy Products of Autologous and Allogeneic Origin”.
• PDA-Advanced Therapy Medicinal Products, Valencia, Spain, 27 – 28 June. Wilfried Dalemans will be chairing a session on “GMP – Current Regulatory Status”.
TiGenix will also attend the following events:
• European Medicines Agency: The First Anniversary of Prime, London, UK, May 19
• FDA Open Seminar: Opportunities Ahead, Barcelona, Spain, June 1 – 2
• Jefferies 2017 Global Healthcare Conference: New York, US, June 6 – 9
• American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting, Seattle, US, June 10 – 14
• International Symposium on Stem Cell Therapy Cardiovascular Innovations, Madrid, Spain, June 15 – 16
• Bio International Convention, San Diego, US, June 19 – 22
• Future Cell Therapy Commercialization Summit, Boston, US, June 26 – 28
A full list of TiGenix events can be found on the website at www.tigenix.com/news-media/news-events/
For more information
Claudia D’Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions.
TiGenix´ lead product, Cx601, has successfully completed a European Phase III clinical trial for the treatment of complex perianal fistulas - a severe, debilitating complication of Crohn’s disease. Cx601 has been filed for regulatory approval in Europe and a global Phase III trial intended to support a future U.S. Biologic License Application (BLA) is expected to start in 2017. TiGenix has entered into a licensing agreement with Takeda, a global pharmaceutical company active in gastroenterology, under which Takeda acquired the exclusive right to develop and commercialize Cx601 for complex perianal fistulas outside the U.S. TiGenix’ second adipose-derived product, Cx611, is undergoing a Phase I/II trial in severe sepsis – a major cause of mortality in the developed world. Finally, AlloCSC-01, targeting acute ischemic heart disease, has demonstrated positive results in a Phase I/II trial in acute myocardial infarction (AMI). TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit http://www.tigenix.com.
